A — Agilent Technologies, Inc.
Healthcare · ETF XLV · as of 2026-09-21
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Agilent Technologies, Inc.
NYQ
Healthcare · Diagnostics & Research
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems;...
Price & today
$161.94
ATR(14) 4.28 (2.64%)
| Stock today | +3.50% |
| Sector ETF today | +0.37% |
| Residual (stock-specific) | +3.13% |
Sector correlation
| 20-day correlation with XLV | 0.22 |
| 60-day correlation with XLV | 0.33 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $153.59 |
| 20 EMA | $151.63 |
| 50 EMA | $146.27 |
| EMA stack | BULLISH |
| RSI(14) | 69.0 |
| 52-week high distance | +1.04% |
| 52-week low distance | +49.46% |
Signals
| Market F&G | 45.6 |
| Bull% | 12.2% |
| OVTLYR status | SELL (12d) |
| Sector rank | #488 |
| Next earnings | 2026-11-23 (AMC, 63d) |
MarketSmith metrics - our compute
RS Rating
91.7
ADR%
2.8
RMV (tight)
12.0
Ext (ATR>20EMA)
2.4
Rel Vol
124.0%
U/D 50d
1.31
U/D 25d
1.61
Accum/Dist 25d
10 / 4
EPS YoY
+18.0%
LoD dist
113.0
Off 52w High
1.1%
Above 52w Low
49.5%
1W / 1M
+10.3 / +3.6
Avg $Vol 50d
322.0M
Mkt Cap (B)
45.7
Trend 8/8
no
Leads Group
YES
Sector XLV
+0.8% 1W
Base len (VCP)
21wk (10/9)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
163.6
Fwd P/E
24.5
PEG
1.3
Price/Book
5.8
Profit margin
19.6%
ROE
21.3%
Debt/Equity
49.7
Rev growth
+10.0%
Analyst target
$159 (-2%)
Analyst rating
BUY
Institutional %
93.6%
Insider %
0.2%
Float %
97.1%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
6 / 146
Industry
Diagnostics & Research
Float
274.3M
Float turnover 20d
0.9%
Avg $Vol 20d / 50d
393.6M / 322.0M
Days to cover
3.3
Short % float
3.0%
Institutional %
93.6%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | 1.46 | +6% | 1,701.0 | +1% |
| Feb-25 | 1.31 | +2% | 1,681.0 | +1% |
| May-25 | 1.31 | +7% | 1,668.0 | +6% |
| Aug-25 | 1.37 | +4% | 1,738.0 | +10% |
| Nov-25 | 1.59 | +9% | 1,861.0 | +9% |
| Feb-26 | 1.36 | +4% | 1,798.0 | +7% |
| May-26 | 1.49 | +14% | 1,835.0 | +10% |
| Aug-26 | 1.62 | +18% | 1,878.0 | +8% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 21 + Magnetic Bead Purification Kits Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook GlobeNewswire Inc.
- Sep 04 + Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share GlobeNewswire Inc.
- Aug 31 · International Markets and Agilent (A): A Deep Dive for Investors Zacks Investment Research
- Aug 27 + Laboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider GlobeNewswire Inc.
- Aug 06 + [Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) GlobeNewswire Inc.
- Aug 06 + AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine GlobeNewswire Inc.